|
Genedrive PLC on Monday said the Scottish government will invest in two pharmacogenetic testing programmes using its kits. The Manchester-based point of care pharmacogenetic testing company said Scotland’s national scale testing programmes will use the MT-RNR1-ID and CYP2C19-ID kits in NHS Scotland. The Scottish government will spend £800,000 on testing newborn babies with the MT-RNR-ID kit in a phased national rollout over 18 months, beginning in October. It is expected that more than 3,000 babies per year will receive the test in Scotland once fully implemented, Genedrive said. A total of £1.1 million will support CYP2C19 testing in recent stroke patients, including Genedrive’s CYP2C19-ID kit. Chief Executive Officer Gino Miele said: ‘This announcement from the Scottish government is a welcome commitment to the strategic implementation of pharmacogenetic testing into clinical pathways at national scale in NHS Scotland. Aside from enabling significantly better patient outcomes, these interventional testing paradigms offer substantial financial value to pressured healthcare systems.’ On Friday, Genedrive said the CYP2C19-ID kit has been implemented into the hyperacute and acute stroke units of Peterborough City Hospital for routine clinical use. Shares in Genedrive were up 0.3% to 1.92 pence in London on Monday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
